Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)
🤖 D.R.A.F.T. Summary
Phase 1 study has demonstrated pharmacokinetics (PK) equivalence between SB27 and Keytruda Phase 1 and Phase 3 studies expected to be completed within 2026 INCHEON, Korea — Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints.
Outlets covering this story
Montreal Gazette
CENTER
Only one perspective covered this story — no diversity detected
Side-by-Side Outlet Comparison — Starter+
See how 1 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →